Failed response to repeat intravenous ketamine infusions in geriatric patients with major depressive disorder

Journal of Clinical Psychopharmacology

Volumn 34, Issue 2, 2014, Pages 285-286

  Szymkowicz, Sarah M ^a   Finnegan, Nora ^b   Dale, Roman M ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b Lutheran Hospital Cleveland   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE;

ANTIDEPRESSANT ACTIVITY; ELECTROCONVULSIVE THERAPY; FAMILY HISTORY; GERIATRIC PATIENT; HUMAN; LETTER; MAJOR DEPRESSION; PRIORITY JOURNAL; RELAPSE; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; WHITE MATTER;

AGED; AGING; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MALE; MIDDLE AGED;

EID: 84896389543     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000090     Document Type: Letter

References (17)

1. Ciraulo DA, Evans JA, Qui WQ, et al. Antidepressant treatment of geriatric depression. In: Ciraulo DA, Shader RI, eds. Pharmacotherapy of Depression. 2nd Edition. New York, NY: Humana Press; 2011: 125-183.
2. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47: 351-354.
3. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63: 856-864.
4. Messer MM, Haller IV. Maintenance ketamine treatment produces long-term recovery from depression. Primary Psychiatry. 2010;17: 48-50.
5. Messer M, Haller IV, Larson P, et al. The use of a series of ketamine infusions in two patients with treatment-resistant depression. J Neuropsychiatry Clin Neurosci. 2010;22: 442-444.
6. aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67: 139-145.
7. Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74: 250-256.
8. Murrough JW. Ketamine as a novel antidepressant: from synapse to behavior. Clin Pharmacol Ther. 2012;91: 303-309.
9. Szymkowicz SM, Finnegan N, Dale RM. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression. J Affect Disord. 2013;147: 416-420.
10. Magnusson KR, Brim BL, Das SR. Selective vulnerabilities of N-methyl-D-aspartate (NMDA) receptors during brain aging. Front Aging Neurosci. 2010;2: 1-15.
11. Maeng S, Zarate CA Jr, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3- hydroxy-5- methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008;63: 349-352.
12. Koike H, Iijima M, Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res. 2011;224: 107-111.
13. Magnusson KR, Scanga C, Wagner AE, et al. Changes in anesthetic sensitivity and glutamate receptors in the aging canine brain. J Gerontol A Biol Sci Med Sci. 2000;55: B448YB454.
14. Green SM, Li J. Ketamine in adults: what emergency physicians need to know about patient selection and emergence reactions. Acad Emerg Med. 2000;7: 278-281.
15. Sachs-Ericsson N, Corsentino E, Moxley J, et al. A longitudinal study of differences in late- and early-onset geriatric depression: depressive symptoms and psychosocial, cognitive, and neurological functioning. Aging Ment Health. 2013;17: 1-11.
16. Dillon C, Allegri RF, Serrano CM, et al. Late- versus early-onset geriatric depression in a memory research center. Neuropsychiatr Dis Treat. 2009;5: 517-526.
17. Lenze EJ. Comorbidity of depression and anxiety in the elderly. Curr Psychiatry Rep. 2003;5: 62-67.